Everything below concerns Replicative senescence. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-05-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
Human data are limited to small studies, often without the randomization, blinding, or control groups expected in contemporary clinical research. Reported outcomes have included changes in melatonin levels, immune markers, and subjective measures, but sample sizes were generally too small to support firm conclusions. Some reviews treat the peptide as promising while noting methodological weaknesses; others question whether the observed effects are specific. The compound is frequently discussed in longevity-focused communities, where enthusiasm often outpaces the published evidence. Separating established findings from speculation is therefore important when reading summaries of this research.
Epitalon emerged from research conducted in Saint Petersburg by Vladimir Khavinson and colleagues, who studied short peptides as potential regulators of aging. The work built on epithalamin, a pineal gland extract reported to influence neuroendocrine function. Epitalon was designed as a synthetic counterpart with a defined sequence, allowing reproducible experiments that extracts could not support. Early publications described effects on melatonin rhythms and lifespan in animal models. These findings circulated mainly in Russian-language journals during the 1990s, which limited their visibility among English-speaking researchers.
The most widely cited claim is that epitalon activates telomerase and thereby extends telomere length. Supporting evidence comes largely from cultured human cells, where treatment was associated with increased telomerase activity and delayed replicative senescence. Telomerase activation is a biologically consequential effect, since the enzyme is largely silenced in most somatic cells. However, the route by which a short peptide would reach and act on the enzyme's regulatory machinery has not been established. Independent replication in human trials is scarce, so the link between cell-culture observations and whole-body aging remains an open question.
Interest in epitalon is usually discussed within the broader field of short peptide bioregulators, a category that includes other synthetic di-, tri-, and tetrapeptides studied by the same research group. These compounds share a common rationale: that small fragments of tissue-derived proteins can retain biological activity and can be produced reproducibly. The category as a whole remains outside mainstream pharmacological consensus, and epitalon specifically has a limited presence in independent, non-Russian research literature, which shapes how its evidence base is described.
Epitalon is a synthetic tetrapeptide with the amino acid sequence alanine-glutamate-aspartate-glycine, abbreviated Ala-Glu-Asp-Gly or AEDG. It was developed by the Russian researcher Vladimir Khavinson and colleagues during work on peptide bioregulators derived from the pineal gland. The compound is short enough to be produced by standard solid-phase peptide synthesis and is typically handled as a lyophilized white powder. Its small size distinguishes it from larger pineal peptides such as epithalamin, a complex extract from which the tetrapeptide was conceptually derived.
| Property | Value | Notes |
|---|---|---|
| Peptide sequence | Ala-Glu-Asp-Gly | Single-letter form AEDG |
| Compound class | Synthetic tetrapeptide | Not a natural free peptide |
| Research origin | Russian gerontology institutes | Developed during the 1990s |
| Main research claim | Telomerase activation | Evidence mainly from cultured cells |
| Regulatory status | Not an approved drug | Handled as a research material |
Short peptides such as AEDG are normally supplied as a freeze-dried solid and are kept dry, cold, and shielded from light. Holding at minus twenty degrees Celsius is common for the long term, while a refrigerator suffices for brief periods before use. The material takes up moisture to some degree, so containers should stay sealed and be allowed to reach room temperature before opening, which limits condensation on the contents. Repeated warming and cooling of a single container is discouraged because it admits water and can lower the amount of intact peptide.
Dissolution is usually performed in water or a suitable aqueous buffer, and the resulting liquid is divided into single-use portions before freezing. Freeze-thaw cycling is a recognised source of loss for short peptides, since each cycle can encourage aggregation or adsorption onto container walls. Working solutions are generally kept cold and used within a short window, although published stability data specific to epitalon are thin. Containers should be marked with concentration and date, and solutions examined for cloudiness before use.
Reported biological findings come mainly from cell culture and rodent experiments. Those studies describe changes in telomerase catalytic subunit expression, melatonin rhythm amplitude, and antioxidant enzyme activity after peptide exposure. Human data are sparse and consist of small trials with limited blinding and inconsistent endpoints. The proposed mechanisms remain hypotheses rather than established facts, and there is no consensus on whether effects observed in animals carry over to people. Independent replication outside the original research groups is limited, which is a recognised gap in the published literature.
The parent extract epithalamin was characterised as a low-molecular-weight fraction of pineal tissue rather than a single defined chemical entity. Researchers fractionated it and tested successive fragments for activity, a screening approach typical of peptide discovery work in that era. Epitalon emerged from that process as one of the shorter sequences of interest. Because the original extract was never fully resolved into individual components, claims about which constituent drives a given effect rest on inference. This distinction matters when reading older reports that attribute extract observations to the tetrapeptide itself.
Epitalon is a synthetic tetrapeptide with the residue sequence alanine-glutamate-aspartate-glycine, commonly abbreviated AEDG. Its monoisotopic mass is approximately 390.35 daltons, and it is usually supplied as a lyophilised trifluoroacetate or acetate salt. The compound was derived from a pineal gland extract called epithalamin, a heterogeneous preparation investigated in the former Soviet Union. Researchers associated with the Saint Petersburg Institute of Bioregulation and Gerontology described the tetrapeptide as a constituent fragment of that extract. Commercial material is offered as a laboratory reagent rather than as a finished pharmaceutical product.
=== Clinical exposure === Gliotoxin is toxic if swallowed or inhaled, and can cause skin and eye irritation if exposure occurs to these areas. The oral LD50 of gliotoxin is 67 mg/kg. Acute symptoms of gliotoxin start rapidly after ingestion.
== Bibliography == Bogle, James and Joanna. (1990). A Heart for Europe: The Lives of Emperor Charles and Empress Zita of Austria-Hungary, Fowler Wright, 1990, ISBN 0-85244-173-8 Brook-Shepherd, Gordon. (1991). The Last Empress: The Life and Times of Zita of Austria-Hungary 1893–1989. Harper-Collins. ISBN 0-00-215861-2 Harding, Bertita. (1939). Imperial Twilight: The Story of Karl and Zita of Hungary. Bobbs-Merrill Company Publishers. ASIN: B000J0DDQO (in German) Bernhard A. Macek: Kaiser Karl I. Der letzte Kaiser Österreichs. Ein biografischer Bilderbogen, Sutton Verlag, Erfurt 2012, ISBN 978-3-9540-0076-0 (in French) Debris, Cyrille. (2013). Zita, Portrait intime d'une imperatrice. Cerf, Paris, 2013, ISBN 978-2-204-10085-4
The PTI- and ETI-signaling pathways are used in conjunction with DAMPs to rapidly signal the rest of the plant to activate its innate immune response and fight off the invading pathogen or mediate the healing process from damage caused by trauma. Plant DAMPs and their receptors are characterized as:
=== Ribosomal diseases and cancer === Ribosomopathies are congenital human disorders resulting from defects in ribosomal protein or rRNA genes, or other genes whose products are implicated in ribosome biogenesis. Examples include X-linked Dyskeratosis congenita (X-DC), Diamond–Blackfan anemia, Treacher Collins syndrome (TCS) and Shwachman–Bodian–Diamond syndrome (SBDS). SBDS is caused by mutations in the SBDS protein that affects its ability to couple GTP hydrolysis by the GTPase EFL1 to the release of eIF6 from the 60S subunit.
Sources: en.wikipedia.org
== Good country == The Good Country Index seeks to measure every country's "contribution to the common good of humanity and the planet". Of 153 nations ranked in 2018, Thailand ranked 60 (1=best; 153=worst). Other ASEAN nations were ranked: Singapore, 23; Malaysia, 45; Philippines, 69; Brunei, 70; Indonesia, 87; Vietnam, 116; Cambodia, 130; Laos, 134. Myanmar was not included due to lack of data.
The surgeon fabricates a metal foil template derived from the dimensions of the nasal wound. Applying a Doppler ultrasonic scanner, the surgeon identifies the axial pedicle of the tissue-flap (composed of the supraorbital artery and the supratrochlear artery), usually at the base, next to the medial brow; the point usually is between the midline and the supraorbital notch. Tracing the Doppler pulse of the blood flow of the supraorbital artery as far as possible, its delineation is continued as a vertical line, until it intersects with the hairline of the patient. The line extended from the pulse of the blood flow is the central axis of the forehead flap. The length of the flap is determined by placing an un-folded, un-stretched 4 × 4-inch gauze upon the wound, and with it measuring from the pedicle base to the distal (farthest) point of the wound. This measure is the length of the central axis of the skin flap. The template is rotated 180 degrees and placed over the distal (far) portion of the axis of the skin flap; the surgeon outlines it with a surgical marker. The outline markings are continued proximally and parallel to the central axis, maintaining a 2-cm width for the proximal flap. Without applying an injection of anaesthetic epinephrine, the flap is incised (cut), and the distal one-half is elevated between the frontalis muscle and the subcutaneous fat. At approximately the mid-portion of the forehead, the surgeon deepens the plane of the dissection down to the submuscular plane.
RCH2=CH2CO-CoA + NADPH + H+ The two substrates of this enzyme are an acyl-CoA and oxidised nicotinamide adenine dinucleotide phosphate (NADP+). Its products are the corresponding 2,3-dehydroacyl-CoA, reduced NADPH, and a proton. The enzyme does not alter the length of the chain attached to coenzyme A but creates a double bond adjacent to the carbonyl group. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-CH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is acyl-CoA:NADP+ 2-oxidoreductase. Other names in common use include 2-enoyl-CoA reductase, dehydrogenase, acyl coenzyme A (nicotinamide adenine dinucleotide, phosphate), enoyl coenzyme A reductase, crotonyl coenzyme A reductase, crotonyl-CoA reductase, and acyl-CoA dehydrogenase (NADP+).
Sources: en.wikipedia.org
Vladimir Khavinson and colleagues at research institutes in Saint Petersburg developed and studied the peptide. Their program examined short peptides as regulators of aging and neuroendocrine function. Epitalon was one of several compounds produced by that group.
That question is not settled. Cell culture studies have reported increased telomerase activity after treatment, but comparable evidence from controlled human trials is lacking. Any claim about telomere lengthening in people should be treated as unproven.
It has not completed the large, controlled trials required for drug approval in major jurisdictions. Most human reports involve small samples and limited follow-up. As a result, it is sold as a research chemical rather than a licensed pharmaceutical product.
Epitalon is a synthetic tetrapeptide composed of four amino acids: alanine, glutamate, aspartate, and glycine. It is written as Ala-Glu-Asp-Gly. The free peptide has a molecular weight of about 390 daltons and is normally supplied as a lyophilized powder.